Trabedersen (AP12009), a TGF-β2 phosphorothioate-modified ASO, has been used as an intratumoral injectable in clinical trials for testing its safety and the tolerability of aggressive tumors shown to express high levels of TGF-β2 mRNA (in colorectal neoplasm, melanoma, PC) (NCT00844064), for efficacy and safety in patients with recurrent or refractory anaplastic astrocytoma or secondary GBM (NCT00431561, NCT00761280) [450], and in combination with Atezolizumab for the treatment of metastatic or recurrent NSCLC (NCT05935774, study withdrawn). This evidence concerns the gene TGFB2 and pachyonychia congenita.